ANL 31.81 Decreased By ▼ -0.40 (-1.24%)
ASC 19.19 Increased By ▲ 0.54 (2.9%)
ASL 28.10 Increased By ▲ 1.65 (6.24%)
AVN 90.70 Decreased By ▼ -0.65 (-0.71%)
BOP 8.50 Increased By ▲ 0.29 (3.53%)
BYCO 12.83 Increased By ▲ 0.99 (8.36%)
DGKC 128.60 Increased By ▲ 2.60 (2.06%)
EPCL 47.80 Decreased By ▼ -0.40 (-0.83%)
FCCL 24.37 Increased By ▲ 0.41 (1.71%)
FFBL 26.60 Decreased By ▼ -1.30 (-4.66%)
FFL 17.85 Increased By ▲ 0.06 (0.34%)
HASCOL 11.75 Increased By ▲ 0.30 (2.62%)
HUBC 78.51 Increased By ▲ 0.21 (0.27%)
HUMNL 8.68 Increased By ▲ 0.04 (0.46%)
JSCL 24.60 Decreased By ▼ -0.05 (-0.2%)
KAPCO 44.01 Decreased By ▼ -0.74 (-1.65%)
KEL 4.22 Increased By ▲ 0.03 (0.72%)
LOTCHEM 15.85 Decreased By ▼ -0.46 (-2.82%)
MLCF 48.90 Increased By ▲ 2.20 (4.71%)
PAEL 36.75 Increased By ▲ 0.55 (1.52%)
PIBTL 11.40 Increased By ▲ 0.36 (3.26%)
POWER 10.59 Increased By ▲ 0.51 (5.06%)
PPL 94.50 Increased By ▲ 4.30 (4.77%)
PRL 27.39 Increased By ▲ 1.14 (4.34%)
PTC 13.42 Decreased By ▼ -0.58 (-4.14%)
SILK 1.62 Increased By ▲ 0.04 (2.53%)
SNGP 50.48 Increased By ▲ 2.28 (4.73%)
TRG 162.50 Decreased By ▼ -6.00 (-3.56%)
UNITY 48.45 Decreased By ▼ -0.94 (-1.9%)
WTL 4.23 Decreased By ▼ -0.03 (-0.7%)
BR100 5,331 Increased By ▲ 48.9 (0.93%)
BR30 27,772 Increased By ▲ 170.83 (0.62%)
KSE100 48,726 Increased By ▲ 421.36 (0.87%)
KSE30 19,647 Increased By ▲ 168.7 (0.87%)

BEIJING: Nearly a million people have taken an experimental coronavirus vaccine developed by Chinese company Sinopharm, the firm said, although it has not yet provided any clear clinical evidence of efficacy. China has been giving experimental Covid-19 vaccines to people including state employees, international students and essential workers heading abroad since July.

Sinopharm's chairman told media this week that nearly a million people have now received their vaccine for emergency use, though he did not provide a specific figure.

"We have not received a single report of severe adverse reaction, and only a few had some mild symptoms," Liu Jingzhen said in an interview re-published by the state-owned firm on Wednesday.

China has been bullish about the development of its vaccine for the new virus - which first emerged in the centre of the country late last year - with four vaccines now in late-stage testing. Many of the trials are taking place overseas, as China has largely brought the virus under control within its borders.